

DarioHealth Disruptive Technology in Chronic Condition Management

We are a leading global digital therapeutics company revolutionizing the management of chronic conditions such as pre-diabetes, diabetes and hypertension. The Company's software-based technology, MyDario, converts a mobile phone into a medical device and service platform which empowers individuals to adjust their lifestyle with healthier choices and more formalized care to better manage their chronic conditions.

Importantly, the Company's software captures, monitors and communicates personalized health data and metrics to its users, using precision data analytics to interpret their data and provide high quality digital and personalized coaching that help users make the best choices for their health.



DarioHealth's cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver seamlessly integrated and highly engaging digital therapeutic interventions.

Digital Therapeutics (DTx) offer a novel means of treating costly Chronic Disease (CD)

\$9B

CD is fueling the growth of DTx Market expanding 21% (CAGR) annually and estimated to reach \$9B by 2025

110M


Projected U.S. users of digital therapeutics by 2023*

77%

Of physicians in the U.S. have successfully recommended digital therapeutics to patients

US Consumer Use Of Digital Therapeutics Is Projected To Rise Rapidly Through 2023

Consumer adoption, millions



Dario's Platform Engagement The Key to Success

Experience & Satisfaction lead to high user engagement



High Engagement leads to clinical improvement



Clinical Improvement leads to less expensive patient care



Data capture from user experience and controlled clinical trials show beneficial clinical outcomes and resulting savings

Fast Facts – Jan. 29, 2020

Ticker (Exchange)	Listing: DRIO (NASDAQ)
Stock Price (USD)	\$8.00
Market Cap	\$60.4M*
Cash (as of 9/30/19)	\$4.6M
<small>Cash figure does not include \$21.3M financing Dec'19</small>	
Outstanding Shares	2.23M
52-Week Range	\$3.44 - \$18.60
Avg. Daily Volume	140,000 (3 mo.)

All figures as of close of trading 1/29/2020 (Source: S&P Capital IQ)
*Fully diluted

Investment Highlights

Product Excellence

- DarioHealth developed a state-of-the-art technology platform that complements current standard of care to better manage chronic conditions. 40K active paying users.

Proven Benefits

- Dario has demonstrated through clinical trials that it can meaningfully impact chronic conditions, resulting in better outcomes and lower costs for patients and payers.

Proven Business Model

- Scalable SaaS platform and membership plans drive attractive high margin, annuity-like cash flow streams.

Compelling Growth Opportunities

- Dario's digital health platform has potential applications in multiple chronic conditions such as diabetes, hypertension and obesity that can be treated in a similar manner.

Global Market Opportunity

- Digital health market is expected to be worth \$423B by 2024.

Strong Balance Sheet

- \$21.3M financing funds strategic plan, including B2B initiative.

A Holistic, Integrated Service For Chronic Disease Management
Proprietary Medical Device, Mobile Application, Digital and Human Coaching



DarioHealth is rapidly expanding its solutions for additional chronic conditions, including hypertension, while penetrating new sales channels and moving into new geographic markets.

The Dario Solution Expands To Fit Additional Chronic Conditions

Our evidence-based digital therapeutic interventions put the user at the center providing tailored coaching and personal support backed by sophisticated software. This approach offers users a unique and highly personalized experience that results in greater engagement and improved clinical outcomes. We can apply the same core principles from our current diabetes and hypertension offerings to other related conditions like pre-diabetes and obesity.



Sales Channels As a Growth Strategy

Direct to Consumer

B2C

- Market Places (Amazon)
- Search based Shopping
- Affiliations & Industry Groups
 - ✓ American Diabetes Assoc.
 - ✓ Digital Therapeutics Alliance
- Social Media
 - ✓ Instagram
 - ✓ Twitter
 - ✓ Facebook
- Brand Ambassadors

Strategic Partnerships

B2B2C

- Distributors
- Providers
- Payers & Employee
- Retailers



Recent News

Jan. 9, 2020 – DarioHealth Strengthens Management Team With Appointment of Digital Health Veteran Rick Anderson as President and G.M. of North America

Dec. 20, 2019 – DarioHealth Closes \$21.3 Million Private Placement

Dec. 3, 2019 – Walmart Starts Distributing the DarioHealth Digital Diabetes Management System

Nov. 25, 2019 – DarioHealth Introduces "Membership-in-a-Box" to Brick and Mortar Retailers

Nov. 14, 2019 – DarioHealth's CEO Erez Raphael to speak at 2019 BTIG Digital Health Conference

Oct. 22, 2019 – DarioHealth Appoints Digital Therapeutics Pioneer Dr. Abigail Hirsch to Its Advisory Board

Executive Management Team

Erez Raphael
President & CEO

Rick Anderson
President & GM North America

Zvi Ben-David
CFO

Investor Contact

Matt Picciano
LifeSci Advisors, LLC
Office: +1 646-889-1200
MPicciano@lifesciadvisors.com

Company Contact

Dario Health Corp.
142 West 57th Street, 8th Floor
New York, New York 10019
P: + 1 888-665-7201
www.DarioHealth.com

Supporter of the:



Member of the:



Forward-Looking Statement Disclaimer

This "Fact Sheet" contains forward-looking statements. You can identify these statements by our use of words such as "may", "expect", "believe", "anticipate", "intend", "could", "estimate", "continue", "plans", or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2018 and Form 10-Q for the quarter ended March 31, 2019.